Veracyte Capital Expenditures vs Begin Period Cash Flow Analysis

VCYT Stock

USD 41.54 2.24 5.12%

Veracyte financial indicator trend analysis is much more than just breaking down Veracyte prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Veracyte is a good investment. Please check the relationship between Veracyte Capital Expenditures and its Begin Period Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.

Capital Expenditures vs Begin Period Cash Flow

Capital Expenditures vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Veracyte Capital Expenditures account and Begin Period Cash Flow. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Veracyte's Capital Expenditures and Begin Period Cash Flow is 0.53. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Veracyte, assuming nothing else is changed. The correlation between historical values of Veracyte's Capital Expenditures and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Veracyte are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Capital Expenditures i.e., Veracyte's Capital Expenditures and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.53

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Veracyte to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Veracyte operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Veracyte's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Veracyte current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.At this time, Veracyte's Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 451.6 K in 2025, whereas Enterprise Value Over EBITDA is likely to drop (43.86) in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	236.0M	333.9M	384.0M	403.2M
Cost Of Revenue	101.6M	112.9M	129.8M	136.3M

Total Operating Expenses Cost Of Revenue

Veracyte fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment
Total Assets		0.98	0.99	1.0	0.74	0.97	-0.68	-0.88	0.93	0.75	0.99	-0.33	0.18	0.77	0.98	0.91	0.95	0.21	0.96	0.98	0.99	0.84	0.9	0.85	0.82	0.97
Other Current Liab	0.98		1.0	0.98	0.69	0.96	-0.58	-0.86	0.96	0.68	0.98	-0.27	0.04	0.69	0.96	0.9	0.92	0.2	0.98	0.97	0.98	0.84	0.93	0.79	0.79	0.98
Total Current Liabilities	0.99	1.0		0.98	0.71	0.96	-0.59	-0.85	0.97	0.68	0.99	-0.32	0.07	0.69	0.96	0.89	0.92	0.2	0.97	0.98	0.97	0.85	0.91	0.79	0.8	0.98
Total Stockholder Equity	1.0	0.98	0.98		0.73	0.97	-0.68	-0.87	0.92	0.75	0.99	-0.33	0.18	0.77	0.98	0.9	0.94	0.19	0.95	0.98	0.99	0.83	0.9	0.85	0.81	0.97
Other Liab	0.74	0.69	0.71	0.73		0.78	-0.71	-0.75	0.61	0.71	0.69	-0.5	0.46	0.72	0.76	0.78	0.75	0.51	0.64	0.76	0.74	0.86	0.54	0.76	0.84	0.72
Property Plant And Equipment Net	0.97	0.96	0.96	0.97	0.78		-0.7	-0.94	0.89	0.79	0.94	-0.27	0.21	0.8	0.99	0.96	0.98	0.35	0.97	0.94	0.99	0.86	0.91	0.88	0.87	0.98
Net Debt	-0.68	-0.58	-0.59	-0.68	-0.71	-0.7		0.7	-0.51	-0.98	-0.56	0.06	-0.65	-0.98	-0.68	-0.77	-0.74	-0.22	-0.61	-0.58	-0.69	-0.56	-0.56	-0.95	-0.76	-0.57
Retained Earnings	-0.88	-0.86	-0.85	-0.87	-0.75	-0.94	0.7		-0.77	-0.76	-0.84	0.2	-0.29	-0.78	-0.93	-0.93	-0.97	-0.44	-0.89	-0.84	-0.93	-0.86	-0.83	-0.84	-0.9	-0.9
Accounts Payable	0.93	0.96	0.97	0.92	0.61	0.89	-0.51	-0.77		0.6	0.94	-0.25	-0.03	0.62	0.89	0.84	0.84	0.12	0.94	0.93	0.91	0.79	0.89	0.71	0.73	0.93
Cash	0.75	0.68	0.68	0.75	0.71	0.79	-0.98	-0.76	0.6		0.64	-0.01	0.55	1.0	0.76	0.85	0.82	0.28	0.72	0.67	0.78	0.6	0.68	0.98	0.78	0.67
Non Current Assets Total	0.99	0.98	0.99	0.99	0.69	0.94	-0.56	-0.84	0.94	0.64		-0.38	0.08	0.66	0.96	0.86	0.91	0.17	0.94	0.99	0.97	0.84	0.89	0.76	0.76	0.97
Non Currrent Assets Other	-0.33	-0.27	-0.32	-0.33	-0.5	-0.27	0.06	0.2	-0.25	-0.01	-0.38		-0.39	-0.05	-0.31	-0.21	-0.2	-0.3	-0.13	-0.4	-0.27	-0.51	0.07	-0.11	-0.31	-0.29
Other Assets	0.18	0.04	0.07	0.18	0.46	0.21	-0.65	-0.29	-0.03	0.55	0.08	-0.39		0.57	0.22	0.32	0.27	0.34	0.04	0.08	0.19	0.27	-0.13	0.5	0.41	0.08
Cash And Short Term Investments	0.77	0.69	0.69	0.77	0.72	0.8	-0.98	-0.78	0.62	1.0	0.66	-0.05	0.57		0.78	0.86	0.83	0.28	0.73	0.68	0.79	0.62	0.68	0.99	0.8	0.69
Net Receivables	0.98	0.96	0.96	0.98	0.76	0.99	-0.68	-0.93	0.89	0.76	0.96	-0.31	0.22	0.78		0.95	0.98	0.35	0.96	0.95	0.99	0.88	0.9	0.87	0.87	0.97
Common Stock Total Equity	0.91	0.9	0.89	0.9	0.78	0.96	-0.77	-0.93	0.84	0.85	0.86	-0.21	0.32	0.86	0.95		0.96	0.48	0.92	0.87	0.94	0.87	0.85	0.92	0.93	0.92
Common Stock Shares Outstanding	0.95	0.92	0.92	0.94	0.75	0.98	-0.74	-0.97	0.84	0.82	0.91	-0.2	0.27	0.83	0.98	0.96		0.37	0.95	0.9	0.98	0.83	0.89	0.9	0.87	0.95
Non Current Liabilities Total	0.21	0.2	0.2	0.19	0.51	0.35	-0.22	-0.44	0.12	0.28	0.17	-0.3	0.34	0.28	0.35	0.48	0.37		0.22	0.25	0.26	0.53	0.11	0.3	0.49	0.31
Inventory	0.96	0.98	0.97	0.95	0.64	0.97	-0.61	-0.89	0.94	0.72	0.94	-0.13	0.04	0.73	0.96	0.92	0.95	0.22		0.92	0.97	0.8	0.96	0.82	0.81	0.97
Other Current Assets	0.98	0.97	0.98	0.98	0.76	0.94	-0.58	-0.84	0.93	0.67	0.99	-0.4	0.08	0.68	0.95	0.87	0.9	0.25	0.92		0.96	0.86	0.88	0.77	0.78	0.97
Other Stockholder Equity	0.99	0.98	0.97	0.99	0.74	0.99	-0.69	-0.93	0.91	0.78	0.97	-0.27	0.19	0.79	0.99	0.94	0.98	0.26	0.97	0.96		0.85	0.92	0.87	0.84	0.98
Total Liab	0.84	0.84	0.85	0.83	0.86	0.86	-0.56	-0.86	0.79	0.6	0.84	-0.51	0.27	0.62	0.88	0.87	0.83	0.53	0.8	0.86	0.85		0.68	0.71	0.93	0.87
Property Plant And Equipment Gross	0.9	0.93	0.91	0.9	0.54	0.91	-0.56	-0.83	0.89	0.68	0.89	0.07	-0.13	0.68	0.9	0.85	0.89	0.11	0.96	0.88	0.92	0.68		0.77	0.7	0.92
Total Current Assets	0.85	0.79	0.79	0.85	0.76	0.88	-0.95	-0.84	0.71	0.98	0.76	-0.11	0.5	0.99	0.87	0.92	0.9	0.3	0.82	0.77	0.87	0.71	0.77		0.84	0.79
Common Stock	0.82	0.79	0.8	0.81	0.84	0.87	-0.76	-0.9	0.73	0.78	0.76	-0.31	0.41	0.8	0.87	0.93	0.87	0.49	0.81	0.78	0.84	0.93	0.7	0.84		0.82
Property Plant Equipment	0.97	0.98	0.98	0.97	0.72	0.98	-0.57	-0.9	0.93	0.67	0.97	-0.29	0.08	0.69	0.97	0.92	0.95	0.31	0.97	0.97	0.98	0.87	0.92	0.79	0.82

Click cells to compare fundamentals

Veracyte Account Relationship Matchups

Veracyte fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	457.2M	1.2B	1.2B	1.1B	1.3B	1.3B
Other Current Liab	10.1M	38.8M	40.0M	41.2M	47.4M	49.7M
Total Current Liabilities	16.8M	64.2M	62.6M	61.2M	70.4M	73.9M
Total Stockholder Equity	421.2M	1.1B	1.1B	1.0B	1.2B	1.3B
Other Liab	6.1M	8.4M	13.1M	7.6M	8.7M	5.6M
Property Plant And Equipment Net	16.8M	31.1M	30.9M	30.9M	35.5M	37.3M
Net Debt	(337.0M)	(154.3M)	(139.5M)	(203.8M)	(183.4M)	(174.3M)
Retained Earnings	(281.6M)	(357.2M)	(393.7M)	(468.1M)	(421.3M)	(400.2M)
Accounts Payable	3.1M	12.4M	11.9M	12.9M	14.9M	15.6M
Cash	349.4M	173.2M	154.2M	216.5M	248.9M	261.4M
Non Current Assets Total	81.5M	944.7M	907.8M	829.3M	953.7M	1.0B
Non Currrent Assets Other	2.0M	(35.1M)	(26.8M)	6.8M	6.2M	6.5M
Other Assets	9.8M	2.9M	6.2M	1.0	1.15	1.09
Cash And Short Term Investments	349.4M	173.2M	178.9M	216.5M	248.9M	261.4M
Net Receivables	18.5M	41.5M	44.0M	40.4M	46.4M	48.8M
Common Stock Total Equity	50K	58K	71K	72K	82.8K	86.9K
Common Stock Shares Outstanding	53.2M	67.9M	71.5M	72.6M	83.5M	87.7M
Liabilities And Stockholders Equity	457.2M	1.2B	1.2B	1.1B	1.3B	1.3B
Non Current Liabilities Total	19.2M	27.2M	18.6M	9.6M	11.0M	17.6M
Inventory	4.7M	11.2M	14.3M	16.1M	18.5M	19.5M
Other Current Assets	3.2M	17.2M	11.5M	12.7M	14.6M	15.3M
Other Stockholder Equity	702.8M	1.5B	1.5B	1.5B	1.8B	1.9B
Total Liab	35.9M	91.3M	81.2M	70.8M	81.4M	44.5M
Property Plant And Equipment Gross	9.0M	31.1M	30.9M	63.7M	73.3M	76.9M
Total Current Assets	375.7M	243.1M	248.6M	285.6M	328.5M	344.9M
Common Stock	58K	71K	72K	73K	84.0K	42.9K
Property Plant Equipment	8.9M	9.0M	31.1M	30.9M	35.5M	37.3M
Short Long Term Debt Total	12.3M	18.9M	14.7M	12.6M	14.5M	16.8M
Net Tangible Assets	171.7M	358.6M	185.9M	379.3M	436.2M	458.0M
Retained Earnings Total Equity	(246.7M)	(281.6M)	(357.2M)	(393.7M)	(354.3M)	(372.1M)
Capital Surpluse	486.1M	702.8M	1.5B	1.5B	1.7B	1.8B
Intangible Assets	59.9M	202.7M	174.9M	88.6M	101.9M	66.2M
Short Term Debt	3.2M	8.4M	8.1M	5.1M	4.6M	7.1M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Veracyte Stock Analysis

When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC